DNMT3A News and Research

RSS

FoundationOne Heme identifies clinically actionable genomic alterations in multiple myeloma cases

Foundation Medicine today announced new data from a pilot study demonstrating that its fully informative genomic profile for hematologic malignancies, FoundationOne Heme, identified both novel and previously reported clinically actionable genomic alterations in multiple myeloma cases. These data were presented in an oral presentation titled Pilot Study To Evaluate The Prevalence Of Actionable Oncogenic Mutations In Patients With Relapsed Refractory Multiple Myeloma (abstract number 755) by Alexander Lesokhin, M.D., medical oncologist, Memorial Sloan-Kettering Cancer Center, at the 55th American Society of Hematology Annual Meeting in New Orleans.

10 Dec 2013

Research findings pave the way for developing better treatments for AML

A team of researchers led by Washington University School of Medicine in St. Louis has identified virtually all of the major mutations that drive acute myeloid leukemia, a fast-growing blood cancer in adults that often is difficult to treat.

2 May 2013

Findings set the stage for identifying potential new drug targets, treatment strategies for AML

nvestigators for The Cancer Genome Atlas Research Network have detailed and broadly classified the genomic alterations that frequently underlie the development of acute myeloid leukemia, a deadly cancer of the blood and bone marrow.

2 May 2013

Details about genomic landscapes of AML and endometrial cancer revealed

Two studies from The Cancer Genome Atlas program reveal details about the genomic landscapes of acute myeloid leukemia and endometrial cancer.

2 May 2013

Individualized genomic analysis allows for tailored cancer treatment, new drug research

Just like a massive iceberg jutting out of the ocean, many of cancer's genetic underpinnings remain hidden under the surface, impossible to predict or map from above.

6 Apr 2013

Caltech-led team discovers enzyme responsible for neural crest cell development

During the early developmental stages of vertebrates-animals that have a backbone and spinal column, including humans-cells undergo extensive rearrangements, and some cells migrate over large distances to populate particular areas and assume novel roles as differentiated cell types.

3 Nov 2012

Mutational profiling could determine which AML patients will benefit from dose-intensive chemotherapy

An international group of researchers, including those from Moffitt Cancer Center in Tampa, Fla., have published a paper in the March 14 issue of the New England Journal of Medicine reviewing the results of a study that analyzed mutations in 18 genes of 398 patients who had acute myeloid leukemia.

26 Mar 2012

Exposure to common flame retardant may affect fertility and long-term memory

Mice genetically engineered to be susceptible to autism-like behaviors that were exposed to a common flame retardant were less fertile and their offspring were smaller, less sociable and demonstrated marked deficits in learning and long-term memory when compared with the offspring of normal unexposed mice, a study by researchers at UC Davis has found.

16 Feb 2012

Newly discovered molecular pathway may explain how AML develops

Researchers at UC Santa Barbara have discovered a molecular pathway that may explain how a particularly deadly form of cancer develops. The discovery may lead to new cancer therapies that reprogram cells instead of killing them. The findings are published in a recent paper in the Journal of Biological Chemistry.

30 Jan 2012

GPS at WUSTL now offers new cancer genetic test

Physicians can now take advantage of a new genetics test -- one of the first of its kind to be offered in the United States -- that can help determine the best treatment for cancer patients.

23 Nov 2011

Six new scientists to receive SWCRF grants for cancer research

This year, the Samuel Waxman Cancer Research Foundation awarded individual grants to six new researchers in addition to funding 18 collaborative grants and three ongoing individual grants. The Foundation expanded its scientific grants program to a total of more than $3.1 million.

1 Jul 2011

New discovery can develop diagnostic test to identify gene mutation in AML

Decoding the DNA of a woman who died of acute myeloid leukemia (AML) has led researchers at Washington University School of Medicine in St. Louis to a gene that they found to be commonly altered in many patients who died quickly of the disease.

11 Nov 2010

Molecule called miR-29b could be a potent treatment for acute myeloid leukemia

A new study by Ohio State University cancer researchers shows that boosting the level of a molecule called miR-29b in acute myeloid leukemia (AML) cells can reverse gene changes that trap the cells in an immature, fast growing state of development.

5 Apr 2009

DNMT3A News and Research

FoundationOne Heme identifies clinically actionable genomic alterations in multiple myeloma cases

Research findings pave the way for developing better treatments for AML

Findings set the stage for identifying potential new drug targets, treatment strategies for AML

Details about genomic landscapes of AML and endometrial cancer revealed

Individualized genomic analysis allows for tailored cancer treatment, new drug research

Caltech-led team discovers enzyme responsible for neural crest cell development

Mutational profiling could determine which AML patients will benefit from dose-intensive chemotherapy

Exposure to common flame retardant may affect fertility and long-term memory

Newly discovered molecular pathway may explain how AML develops

GPS at WUSTL now offers new cancer genetic test

Six new scientists to receive SWCRF grants for cancer research

New discovery can develop diagnostic test to identify gene mutation in AML

Molecule called miR-29b could be a potent treatment for acute myeloid leukemia

Innovations in baculovirus–insect cell expression systems

Compound Management and its Crucial Role in Early Pharmaceutical Research

Natural products: the next frontier in drug discovery

Latest News